Background: Epigenetic alterations, including histone modifications, play an important role during carcinogenesis. This study was designed to systematically investigate histone H3K9 and H3K27 methylation levels in bladder cancer (BCa) tissue. Methods: A tissue microarray with urothelial BCa (150 non-muscle-invasive BCa, NMIBC; 121 muscle-invasive BCa, MIBC; 31 metastatic BCa, MET) and normal urothelium (29, CTRL) specimen was used to determine the global levels of H3K9 and H3K27 mono-, di- and tri-methylation. Results: Global levels of H3K9 and H3K27 methylation were significantly higher in CTRL than in BCa, and levels in NMIBC were higher compared to MIBC. Histone methylation levels of MET resembled MIBC. We observed furthermore a correlation of histone methylation levels with pT stage (H3K9me1, H3K9me2, H3K9me3, H3K27me1, H3K27me3) and grade (H3K9me2, H3K9me3, H3K27me1) in NMIBC. H3K9me1, H3K9me3, H3K27me1 and H3K27me3 levels were also correlated with pT stage in MIBC. Histone modifications were not associated with recurrence-free or cancer-specific survival. Conclusions: Global histone H3K9 and H3K27 methylation levels are altered in BCa.

Keywords:
Histone, Methylation, Bladder cancer, H3K9, H3K27
1.
Jeon SH, Jeon SH, Chang SG: Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat 2005;37:48-53.
2.
Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R, Manco R, Ricciardulli S, Nicolai M, Criniti P, Tenaglia RL: Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 2012;89:61-66.
3.
Dudziec E, Goepel JR, Catto JW: Global epigenetic profiling in bladder cancer. Epigenomics 2011;3:35-45.
4.
Kouzarides T: Chromatin modifications and their function. Cell 2007;128:693-705.
5.
Greer EL, Shi Y: Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012;13:343-357.
6.
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-1266.
7.
Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, Müller SC, Ellinger J: Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 2011;108:E290-E296.
8.
Barbisan F, Mazzucchelli R, Santinelli A, Stramazzotti D, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R: Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. Int J Immunopathol Pharmacol 2008;21:615-623.
9.
Cheung WL, Albadine R, Chan T, Sharma R, Netto GJ: Phosphorylated H2AX in noninvasive low grade urothelial carcinoma of the bladder: correlation with tumor recurrence. J Urol 2009;181:1387-1392.
10.
Rogenhofer S, Miersch H, Göke F, Kahl P, Wieland WF, Hofstädter F, Kristiansen G, von Ruecker A, Müller SC, Ellinger J: Histone methylation defines an epigenetic entity in penile squamous cell carcinoma. J Urol 2013;189:1117-1122.
11.
Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ, von Ruecker A: Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-69.
12.
Ellinger J, Kahl P, von der Gathen J, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S: Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest 2012;30:92-97.
13.
Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, Yegnasubramanian S, De Marzo AM: Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol 2012;181:560-569.
14.
Rogenhofer S, Kahl P, Holzapfel S, von Ruecker A, Mueller SC, Ellinger J: Decreased levels of histone H3K9me1 indicate poor prognosis in patients with renal cell carcinoma. Anticancer Res 2012;32:879-886.
15.
Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Büttner R, Müller SC, von Ruecker A, Ellinger J: Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 2012;109:459-465.
16.
Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A, Duan X: Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer 2012;12:470.
17.
Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK: Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-1628.
18.
Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ: The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008;15:1968-1976.
19.
Song JS, Kim YS, Kim DK, Park SI, Jang SJ: Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients. Pathol Int 2012;62:182-190.
20.
Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S, Nakamura Y, Yoshihara M, Sakuma Y, Kameda Y, Akaike M, Yukawa N, Rino Y, Masuda M, Miyagi Y: Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. Eur J Surg Oncol 2013;39:655-661.
21.
Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M: Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol 2012;6:494-506.
22.
Kurdistani SK: Histone modifications in cancer biology and prognosis. Prog Drug Res 2011;67:91-106.
23.
Fillingham J, Keogh MC, Krogan NJ: GammaH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 2006;84:568-577.
24.
Günlüsoy B, Değirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR: Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Urol Int 2005;75:107-113.
25.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, Roupret M: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
26.
van den Bosch S, Alfred Witjes J: Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493-500.
27.
Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K: High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823-837.
28.
Choi SH, Worswick S, Byun HM, Shear T, Soussa JC, Wolff EM, Douer D, Garcia-Manero G, Liang G, Yang AS: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer 2009;125:723-729.
29.
Seifert HH, Schmiemann V, Mueller M, Kazimirek M, Onofre F, Neuhausen A, Florl AR, Ackermann R, Boecking A, Schulz WA, Grote HJ: In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol 2007;82:292-297.
30.
Schuster-Bockler B, Lehner B: Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature 2012;488:504-507.
31.
Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X: Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets 2013;13:558-579.
32.
Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caşkurlu T, Cakir OO, Ergenekon E: Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005;75:252-257.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.